K Blighe
Overview
Explore the profile of K Blighe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
102
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stebbing J, Zhang H, Xu Y, Lit L, Green A, Grothey A, et al.
Oncogene
. 2021 Apr;
40(19):3473.
PMID: 33888869
No abstract available.
2.
Hosseinkhan N, Honardoost M, Blighe K, Moore C, Khamseh M
J Endocrinol Invest
. 2020 Jan;
43(7):911-923.
PMID: 31965517
Purpose: Identification of stage-specific prognostic/predictive biomarkers in papillary thyroid carcinoma (PTC) could lead to its more efficient clinical management. The main objective of this study was to characterize the stage-specific...
3.
Blighe K, DeDionisio L, Christie K, Chawes B, Shareef S, Kakouli-Duarte T, et al.
BMC Genomics
. 2018 Aug;
19(1):595.
PMID: 30086710
The reporting of the first draft of the human genome in 2000 brought with it much hope for the future in what was felt as a paradigm shift toward improved...
4.
Stebbing J, Zhang H, Xu Y, Lit L, Green A, Grothey A, et al.
Oncogene
. 2014 Jun;
34(16):2103-14.
PMID: 24909178
Kinase suppressor of Ras-1 (KSR1) facilitates signal transduction in Ras-dependent cancers, including pancreatic and lung carcinomas but its role in breast cancer has not been well studied. Here, we demonstrate...
5.
Stebbing J, Filipovic A, Lit L, Blighe K, Grothey A, Xu Y, et al.
Oncogene
. 2012 Aug;
32(28):3371-80.
PMID: 22869149
Resistance to endocrine therapy in breast cancer is common. With the aim of discovering new molecular targets for breast cancer therapy, we have recently identified LMTK3 as a regulator of...
6.
Payne R, Hava N, Page K, Blighe K, Ward B, Slade M, et al.
Br J Cancer
. 2011 Dec;
106(2):375-82.
PMID: 22166803
Background: The aim of this study was to gain insight into breast cancer dormancy by examining different measures of minimal residual disease (MRD) over time in relation to known prognostic...
7.
Page K, Hava N, Ward B, Brown J, Guttery D, Ruangpratheep C, et al.
Br J Cancer
. 2011 Mar;
104(8):1342-8.
PMID: 21427727
Background: Human epidermal growth factor receptor 2 (HER2) is amplified and overexpressed in 20-25% of breast cancers. This study investigated circulating free DNA (cfDNA) for detection of HER2 gene amplification...